Speaking to the British Medical Journal, Healthcare Director, Chay Brown, said:
“The trial methodology is inherently coercive and inappropriate in what it is measuring – as though it is designed to reach a negative conclusion. Gender related healthcare for young people has become a mess, treating patients with suspicion and delaying and banning treatments based on treating being trans as a risk rather than natural human variation.
“We support ethical and expansive research on puberty blockers that does not cap the trial numbers, does not have an unmedicated control group, and is measuring health and wellbeing outcomes appropriately.
“As we noted in our initial response to the launch of the trial, the ‘godfather of evidence-based medicine,’ Dr Gordon Guyatt, has said that the early evidence on the use of puberty blockers is not an acceptable reason to withhold their availability.
“In the words of Dr Gordon Guyatt, ‘It is profoundly misguided to cast health care based on low-certainty evidence as bad care or as care driven by ideology, and low-certainty evidence as bad science. Many of the interventions we offer are based on low certainty evidence, and enlightened individuals often legitimately and wisely choose such interventions.’
“Puberty blockers would be considered a highly promising intervention if they weren’t associated with being trans. It is ironic to see the same people who championed the discredited Cass Review now turn on the clear recommendations of that review for further research – yet another sign of how deep anti-trans sentiment has sunk its claws into UK politics.”
– ENDS –
Further information
For further information, please contact jane fae via press@transactual.org.uk.
Opt-in
If you would like to receive future media communications from TransActual, please drop a line to press@transactual.org.uk asking us to add you to our list.